AR086798A1 - Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen - Google Patents

Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen

Info

Publication number
AR086798A1
AR086798A1 ARP120102337A ARP120102337A AR086798A1 AR 086798 A1 AR086798 A1 AR 086798A1 AR P120102337 A ARP120102337 A AR P120102337A AR P120102337 A ARP120102337 A AR P120102337A AR 086798 A1 AR086798 A1 AR 086798A1
Authority
AR
Argentina
Prior art keywords
nrbrb
alkyl
alkoxyalkyl
nrcc
haloalkyl
Prior art date
Application number
ARP120102337A
Other languages
English (en)
Inventor
Suzuki Masaki
Kurimura Muneaki
R Valluru Krishna
Takahashi Akira
Kuroda Takeshi
Takahashi Haruka
Fukushima Tae
Miyamura Shin
Ghosh Indranath
Dogra Abhishek
Harriman Geraldine
Elder Amy
Shimizu Satoshi
J Hodgetts Kevin
S Newcom Jason
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR086798A1 publication Critical patent/AR086798A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), o una sal del mismo, donde: m es 0 ó 1; L es un enlace directo o NR⁶; R¹ es hidrógeno, alquilo C₁₋₈, haloalquilo C₁₋₈, alcoxi C₁₋₈alquilo C₁₋₈, hidroxialquilo C₁₋₈, aminoalquilo C₁₋₈, oxazolilo, tiazolilo, isoxazolilo, piridilo, pirrolopiridilo, oxadiazolilo-alquilo C₁₋₈, piridilo-alquilo C₁₋₈, oxazolilo-alquilo C₁₋₈, fenilo-alquilo C₁₋₈, -C(O)Rᵉ, pirrolidinilo, azetidinilo, indolinilo, piperidinilo, morfolinilo, piperazinilo, fenilo, cicloalquilo C₃₋₈, cicloalquilo C₃₋₈alquilo C₁₋₈, benzoxazolilo, cada uno de los cuales está opcionalmente sustituido con 1 - 2 R⁷; R² es alcoxi C₁₋₈, benzodioxolilo, piperazinilo, halo, fenilo, tetrahidronaftilo, furilo, oxazolilo, tiazolilo, tiadiazolilo, piridilo, pirimidinilo, indolilo, indazolilo, dihidroindazolilo, tetrahidroisoquinolinilo, tetrahidroquinolinilo, dihidrobenzoimidazolilo, dihidrobenzoxazolilo, benzotiazolilo, dihidrobenzotiazolilo, benzotienilo, dihidroisoquinolinilo, isoquinolinilo, benzofurilo, dihidrobenzofurilo, benzodioxolilo, dihidrobenzoxazinilo, dihidrobenzodioxepinilo, tetrahidrobenzoxazepinilo, isoindolinilo, indolinilo, tienilo o dihidrobenzodioxinilo, cada uno de los cuales está opcionalmente sustituido con 1 - 3 R⁹; R³ es piridilo, pirimidinilo, pirazinilo o piridazinilo, cada uno de los cuales está opcionalmente sustituido con alquilo C₁₋₈, alcoxi C₁₋₈, halo, haloalquilo C₁₋₈, haloalcoxi C₁₋₈, ciano o -ORᵈ; R⁴ es hidrógeno, alquilo C₁₋₈, alcoxi C₁₋₈, halo, haloalquilo C₁₋₈ o haloalcoxi C₁₋₈, cada uno de los cuales está opcionalmente sustituido con R¹⁰; R⁶ es hidrógeno o alquilo C₁₋₈; R⁷ es alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, arilo, heteroarilo, ciclilo, heterociclilo, arilalquilo, heteroarilalquilo, ciclilalquilo, heterociclilalquilo, halo, haloalquilo, haloalcoxi, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, hidroxialquilo, alcoxialquilo, oxo, tioxo, -CN, -NO₂, -C(O)ORᵃ, -C(Y)NRᵇRᵇ, -NRᶜC(Y)Rᶜ, NRᵇRᵇ, -OC(O)NRᵇRᵇ, -NRᶜC(O)ORᶜ, -SO₂NRᵇRᵇ, -NRᶜSO₂Rᶜ, -NRᶜC(Y)NRᵇRᵇ, -ORᵈ, -SRᵈ, -C(Y)Rᵉ o S(O)qRᶠ, cada uno de los cuales está opcionalmente sustituido con R¹²; R⁹ es alquilo C₁₋₈, alcoxi C₁₋₈, fenilo, pirazolilo, dihidrobenzoxazolilo, oxazolilo, tetrazolilo, imidazolilo, tiazolilo, cicloalquilo C₃₋₈, oxetanilo, pirrolidinilo, morfolinilo, halo, haloalquilo C₁₋₈, haloalcoxi C₁₋₈, hidroxialquilo C₁₋₈, oxo, ciano, nitro, -C(O)ORᵃ, -C(O)NRᵇRᵇ, -NRᶜC(O)Rᶜ, -NRᵇRᵇ, -ORᵈ, -SRᵈ, -C(O)Rᵉ o S(O)qRᶠ, cada uno de los cuales está opcionalmente sustituido con 1 - 2 R¹²; R¹⁰ es alcoxi C₁₋₈, alquenilo C₂₋₈, cicloalquilo C₃₋₈, furilo, tienilo, pirazolilo, morfolinilo, piperazinilo, pirrolidinilo, piperidinilo, tetrahidropiranilo, ciano, -C(O)NRᵇRᵇ, -NRᶜC(O)Rᶜ, -NRᵇRᵇ o S(O)qRᶠ, cada uno de los cuales está opcionalmente sustituido con R¹²; R¹² es alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, arilo, heteroarilo, ciclilo, heterociclilo, arilalquilo, heteroarilalquilo, ciclilalquilo, heterociclilalquilo, halo, haloalquilo, haloalcoxi, aminoalquilo, alquilaminoalquilo, dialquilaminoalquilo, hidroxialquilo, alcoxialquilo, oxo, tioxo, -CN, -NO₂, -C(O)ORᵃ, -C(Y)NRᵇRᵇ, -NRᶜC(Y)Rᶜ, -NRᵇRᵇ, -OC(O)NRᵇRᵇ, -NRᶜC(O)ORᶜ, -SO₂NRᵇRᵇ, -NRᶜSO₂Rᶜ, -NRᶜC(Y)NRᵇRᵇ,-ORᵈ, -SRᵈ, -C(Y)Rᵉ o S(O)qRᶠ, cada uno de los cuales está opcionalmente sustituido con 1 - 3 R¹³; R¹³ es en forma independiente alquilo C₁₋₈, haloalquilo, halo, heterociclilo, ciclilo, oxo o -C(Y)NRᵇRᵇ; cada Rᵃ, Rᵇ, Rᵇ, Rᶜ, Rᶜ, Rᵈ, Rᵈ, Rᵉ y Rᶠ es en forma independiente hidrógeno, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, acilo, haloalquilo, alcoxialquilo, alquilaminoalquilo, dialquilaminoalquilo, ciclilo, heterociclilo, arilo, heteroarilo, ciclilalquilo, heterociclilalquilo, arilalquilo o heteroarilalquilo; y q es 1 ó 2.
ARP120102337A 2011-06-29 2012-06-28 Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen AR086798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502592P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
AR086798A1 true AR086798A1 (es) 2014-01-22

Family

ID=46690684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102337A AR086798A1 (es) 2011-06-29 2012-06-28 Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen

Country Status (15)

Country Link
US (1) US20140315886A1 (es)
EP (1) EP2726485A1 (es)
JP (1) JP2014522837A (es)
KR (1) KR20140048216A (es)
CN (1) CN103703001A (es)
AR (1) AR086798A1 (es)
BR (1) BR112013033417A2 (es)
CA (1) CA2840627A1 (es)
CO (1) CO6870033A2 (es)
EA (1) EA201490177A1 (es)
MX (1) MX2013015204A (es)
SG (1) SG195200A1 (es)
TW (1) TW201311660A (es)
WO (1) WO2013003586A1 (es)
ZA (1) ZA201308859B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102786512A (zh) * 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3763710A1 (en) 2013-02-20 2021-01-13 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
BR112015022417A2 (pt) 2013-03-14 2017-07-18 Convergene Llc métodos e composições para inibição de proteínas contendo bromodomínio
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
KR101658111B1 (ko) 2013-05-13 2016-09-20 제일모직 주식회사 유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
KR20170117023A (ko) * 2014-12-05 2017-10-20 서브라마니암 아난탄 생체 아민 수송 조절인자로서 헤테로환상 화합물
CA2969974C (en) * 2014-12-15 2020-08-04 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
EP3280708B1 (en) 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017087528A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EP4050005A1 (en) * 2015-11-25 2022-08-31 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3509422A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
BR112019012573A2 (pt) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico que contém asenapina e polissiloxano ou poli-isobutileno
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US20200283444A1 (en) * 2017-08-02 2020-09-10 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
KR20220018004A (ko) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 조절 방출 제형 및 이의 용도
EP4051672A1 (en) * 2019-11-01 2022-09-07 Janssen Biotech, Inc. Fluorinated quinoline and quinoxaline derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases
CN115943144A (zh) * 2020-08-14 2023-04-07 成都海博为药业有限公司 一种作为pak4激酶抑制剂的化合物及其制备方法和应用
CN117295716A (zh) 2020-12-22 2023-12-26 麦克尼斯迪克治疗有限公司 作为egfr和/或pi3k抑制剂的取代氨基苄基杂芳基化合物
US20240174603A1 (en) * 2021-02-08 2024-05-30 Rappta Therapeutics Oy Modulators of protein phosphatase 2a (pp2a) and methods using same
WO2022171018A1 (zh) * 2021-02-09 2022-08-18 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
US20240197888A1 (en) * 2021-03-17 2024-06-20 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
AR126078A1 (es) * 2021-06-04 2023-09-06 Genentech Inc Compuestos de 2,8-diazaspiro[4.5]decano
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用
CN116239577A (zh) * 2023-03-27 2023-06-09 沈阳药科大学 一种制备Cudetaxestat的方法
US11858934B1 (en) 2023-07-17 2024-01-02 King Faisal University Substituted pyrido[4′,3′:5,6]pyrimido[1,2-a]indoles as CK2 inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1390015A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv 4-amino-quinazoline compounds
US3980650A (en) * 1972-05-05 1976-09-14 N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia 4-Amino-pyrimidine derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
WO2004055004A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
EP1685115A1 (en) 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2006050843A1 (en) * 2004-11-09 2006-05-18 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
CN101056865A (zh) * 2004-11-09 2007-10-17 霍夫曼-拉罗奇有限公司 氨基喹唑啉化合物
US20060128702A1 (en) 2004-11-23 2006-06-15 Manojit Pal Heterocyclic and bicyclic compounds, compositions and methods
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
JP2007084494A (ja) 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
AU2007249762A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of CDKI pathway inhibitors
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US20090023773A1 (en) 2007-06-27 2009-01-22 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
MA33330B1 (fr) * 2009-05-29 2012-06-01 Syngenta Participations Ag Quinazolines substituées comme fongicides
SI3575288T1 (sl) * 2009-09-03 2022-01-31 Bristol-Myers Squibb Company Kinazolini kot ionski kanalni inhibitorji kalija
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
WO2012066122A1 (en) * 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides

Also Published As

Publication number Publication date
KR20140048216A (ko) 2014-04-23
US20140315886A1 (en) 2014-10-23
JP2014522837A (ja) 2014-09-08
CO6870033A2 (es) 2014-02-20
EP2726485A1 (en) 2014-05-07
CN103703001A (zh) 2014-04-02
ZA201308859B (en) 2015-02-25
TW201311660A (zh) 2013-03-16
WO2013003586A1 (en) 2013-01-03
BR112013033417A2 (pt) 2016-08-16
WO2013003586A8 (en) 2014-01-03
MX2013015204A (es) 2014-02-17
EA201490177A1 (ru) 2014-08-29
CA2840627A1 (en) 2013-01-03
SG195200A1 (en) 2013-12-30

Similar Documents

Publication Publication Date Title
AR086798A1 (es) Derivados quinazolinicos utiles para tratar trastornos del sistema nervioso central y composiciones farmaceuticas que los contienen
RU2018121834A (ru) Новое соединение бифенила или его соль
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
AR102939A1 (es) 3-oxo-3-(arilamino)propanoatos, proceso para prepararlos, y su uso para preparar pirrolidinonas
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
AR106099A1 (es) Compuestos bicíclicos como inhibidores duales de atx / ca
NZ732810A (en) Picolinamides and other compounds
AR099640A1 (es) Derivados de pirrolopiridina o pirazolopiridina
AR091246A1 (es) Procesos para producir 2-(piridin-3-il)tiazoles
AR099122A1 (es) Derivados de pirimidiniloxi benceno como herbicidas
EA201600234A1 (ru) Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
AR099768A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
AR105544A1 (es) Compuestos de n-carboxamida cíclica útiles como herbicidas
AR076551A1 (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
AR103965A1 (es) Derivados de pirimidiniloxi piridina sustituida como herbicidas
AR064635A1 (es) Derivados de benzotiazolona
AR088625A1 (es) Derivados de aril-quinolina
AR098698A1 (es) Compuestos herbicidas de pirimidiniloxi benceno sustituido
AR087628A1 (es) Inhibidores de pde10 de pirimidina
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
AR095422A1 (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
AR091429A1 (es) Compuestos de fenoxietil piperidina
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
AR090678A1 (es) Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis

Legal Events

Date Code Title Description
FB Suspension of granting procedure